Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding Ltd.    ROG   CH0012032048

ROCHE HOLDING LTD. (ROG)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
07/09/2018 07/10/2018 07/11/2018 07/12/2018 07/13/2018 Date
225.2(c) 225.1(c) 223.3(c) 230.45(c) 232.7(c) Last
1 182 560 1 531 811 1 544 785 2 268 073 1 819 482 Volume
+0.58% -0.04% -0.80% +3.20% +0.98% Change
More quotes
Financials (CHF)
Sales 2018 55 478 M
EBIT 2018 18 453 M
Net income 2018 11 847 M
Debt 2018 4 056 M
Yield 2018 3,70%
Sales 2019 57 135 M
EBIT 2019 18 939 M
Net income 2019 12 527 M
Debt 2019 415 M
Yield 2019 3,77%
P/E ratio 2018 16,36
P/E ratio 2019 15,71
EV / Sales2018 3,70x
EV / Sales2019 3,53x
Capitalization 201 B
More Financials
Company
Roche Holding AG operates as a research healthcare company.It operates through the following segments: Diagnostics and Pharmaceuticals.The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience.The... 
Sector
Pharmaceuticals
Calendar
07/26 | 07:00amEarnings Release
More about the company
Surperformance© ratings of Roche Holding Ltd.
Trading Rating : Investor Rating :
More Ratings
Latest news on ROCHE HOLDING LTD.
07/12GENENTECH : Announces Submission of Supplemental New Drug Application for Vencle..
BU
07/09Trump slams Pfizer after July 1 drug price hikes
RE
07/06HITTING CANCER EARLY : AstraZeneca's bid to outmaneuver rivals
RE
07/06Hitting cancer early - AstraZeneca's bid to outmanoeuvre rivals
RE
07/02ROCHE : Phase III IMpassion130 Study Showed Genentech’s TECENTRIQ Plus Abr..
BU
06/30NOVARTIS CHAIRMAN SAYS ALCON WORTH $ : Finanz und Wirtschaft
RE
06/27ROCHE : Pregnant women could soon be able to rely on the first Canadian-licensed..
AQ
06/26ROCHE : Puma Biotech says Europe likely to approve breast cancer drug
RE
06/26Roche's Genentech Gets FDA Priority Review for Flu Drug
DJ
06/26ROCHE : FDA Grants Priority Review to Genentech’s Baloxavir Marboxil for t..
BU
More news
Sector news : Pharmaceuticals - NEC
07/14INDIVIOR : wins preliminary injunction against generic rival
RE
07/13TEVA PHARMACEUTICAL INDUSTRIES : FDA Recalls Several Medicines That Contain Vals..
DJ
07/13NOVARTIS : Played Down Ties to Trump Lawyer Michael Cohen, Report Says
DJ
07/13JOHNSON & JOHNSON : J&J vows to overturn $4.7 billion talc verdict but experts s..
RE
07/13NOVARTIS : disputes U.S. senators' report on Cohen contract
RE
More sector news : Pharmaceuticals - NEC
4-Traders Strategies on ROCHE HOLDING LTD. 
ROCHE HOLDING LTD. - 2016
An opportunity over the medium term?
BUY
ROCHE HOLDING LTD. - 2016
A medium term support level to take advantage of
BUY
More Strategies
Latest Tweets
07/15Natera $NTRA & Foundation Medicine $FMI Head-To-Head Analysis  
07/14Roche PCT assay cleared for expanded use - Important tool in antibiotic resis.. 
07/13FDA OKs expanded use for Roche's PCT assay  
07/13Head to Head Comparison: Veracyte $VCYT versus Foundation Medicine $FMI  
07/12Today on , Melissa Breslow of Open Eyes Foundation and Mind-Body-Space along ..
1
More tweets
Qtime:189
News from SeekingAlpha
07/15BIOTECH ANALYSIS CENTRAL PHARMA NEWS : Cytodyn's Acquisition, Novartis Exits Ant.. 
07/13FDA OKs expanded use for Roche's PCT assay 
07/13YOUR DAILY PHARMA SCOOP : ResTORbio Progresses, Roche Closer To Review, AbbVie F.. 
07/12Drug prices still marching upward - Bloomberg 
07/12AbbVie files U.S. marketing application for expanded use for Venclexta 
Chart ROCHE HOLDING LTD.
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | ROG | CH0012032048 | 4-Traders
Technical analysis trends ROCHE HOLDING LTD.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 257  CHF
Spread / Average Target 10%
EPS Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.-5.60%200 973
JOHNSON & JOHNSON-8.56%337 763
PFIZER3.59%219 534
NOVARTIS-3.93%201 464
MERCK AND COMPANY11.76%169 193
AMGEN11.60%129 635